Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study
Adebrelimab suggests potentially promising efficacy in ES-SCLC, aligning with pivotal trial data despite an older cohort. ECOG PS ≥2, high metastatic burden, and elevated CRP independently predict poorer outcomes. Vigilant monitoring for hematologic toxicity and rare cardiotoxicity is warranted.
Authors
- Zhigang Weng (ORCID: https://orcid.org/0000-0003-1885-5501)
- Jianxin Chen (ORCID: https://orcid.org/0000-0001-6204-1121)
- Jian Wang (ORCID: https://orcid.org/0000-0001-7620-6740)
- Kaili Xu (ORCID: https://orcid.org/0000-0001-7988-7369)
Institutions
- Quzhou City People's Hospital (CN)
- Quzhou University (CN)
- First Hospital of Jiaxing (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1678020
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00